Covid-19 roundup: Russian biotech seeks permission to produce remdesivir generic; Why did BARDA fund plasma company part-owned by Rick Santorum?
Russian biotech Pharmasyntez is turning to the Kremlin for a way around Gilead’s patent on remdesivir, Reuters reported.
The company has asked Russia for permission to manufacture a generic version of the patented Covid-19 drug without Gilead’s consent, in the interest of national security or defense, according to Reuters. And it’s planning to offer the generic at a steep discount: $540 for a 6-vial course, compared to Gilead’s five-day course at at $3,120, the news agency reported.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.